Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs LY 3016859 (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 20 Aug 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 20 Jan 2015 Planned End Date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 20 Jan 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.